These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 28799854)
1. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Barschke P; Oeckl P; Steinacker P; Ludolph A; Otto M Expert Rev Proteomics; 2017 Sep; 14(9):769-777. PubMed ID: 28799854 [TBL] [Abstract][Full Text] [Related]
2. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. Collins MA; An J; Hood BL; Conrads TP; Bowser RP J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960 [TBL] [Abstract][Full Text] [Related]
3. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Ranganathan S; Nicholl GC; Henry S; Lutka F; Sathanoori R; Lacomis D; Bowser R Amyotroph Lateral Scler; 2007 Dec; 8(6):373-9. PubMed ID: 17852009 [TBL] [Abstract][Full Text] [Related]
4. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. von Neuhoff N; Oumeraci T; Wolf T; Kollewe K; Bewerunge P; Neumann B; Brors B; Bufler J; Wurster U; Schlegelberger B; Dengler R; Zapatka M; Petri S PLoS One; 2012; 7(9):e44401. PubMed ID: 22970211 [TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease. Kolarcik C; Bowser R Mol Diagn Ther; 2006; 10(5):281-92. PubMed ID: 17022691 [TBL] [Abstract][Full Text] [Related]
6. Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Al Shweiki MR; Oeckl P; Steinacker P; Hengerer B; Schönfeldt-Lecuona C; Otto M Expert Rev Proteomics; 2017 Jun; 14(6):499-514. PubMed ID: 28562112 [TBL] [Abstract][Full Text] [Related]
7. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. Ekegren T; Hanrieder J; Bergquist J J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436 [TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Ranganathan S; Williams E; Ganchev P; Gopalakrishnan V; Lacomis D; Urbinelli L; Newhall K; Cudkowicz ME; Brown RH; Bowser R J Neurochem; 2005 Dec; 95(5):1461-71. PubMed ID: 16313519 [TBL] [Abstract][Full Text] [Related]
9. Identification of potential CSF biomarkers in ALS. Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598 [TBL] [Abstract][Full Text] [Related]
10. Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. Costa J; Streich L; Pinto S; Pronto-Laborinho A; Nimtz M; Conradt HS; de Carvalho M Mol Neurobiol; 2019 Aug; 56(8):5729-5739. PubMed ID: 30674035 [TBL] [Abstract][Full Text] [Related]
11. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. Krüger T; Lautenschläger J; Grosskreutz J; Rhode H Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563 [TBL] [Abstract][Full Text] [Related]
12. [Proteomic analysis of the cerebrospinal fluid from patients with amyotrophic lateral sclerosis based on tandem mass spectrometry technique]. Su D; Zhang Y; Bi F; Xiao B Nan Fang Yi Ke Da Xue Xue Bao; 2019 Apr; 39(4):428-436. PubMed ID: 31068286 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis. Kaiserova M; Grambalova Z; Otruba P; Stejskal D; Prikrylova Vranova H; Mares J; Mensikova K; Kanovsky P Acta Neurol Scand; 2017 Oct; 136(4):360-364. PubMed ID: 28185258 [TBL] [Abstract][Full Text] [Related]
14. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Oeckl P; Weydt P; Thal DR; Weishaupt JH; Ludolph AC; Otto M Acta Neuropathol; 2020 Jan; 139(1):119-134. PubMed ID: 31701227 [TBL] [Abstract][Full Text] [Related]
15. Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis? Chełstowska B; Kuźma-Kozakiewicz M Biomarkers; 2014 Nov; 19(7):571-7. PubMed ID: 25133306 [TBL] [Abstract][Full Text] [Related]
16. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899 [TBL] [Abstract][Full Text] [Related]
17. Biochemical markers in CSF of ALS patients. Süssmuth SD; Brettschneider J; Ludolph AC; Tumani H Curr Med Chem; 2008; 15(18):1788-801. PubMed ID: 18691039 [TBL] [Abstract][Full Text] [Related]
18. A pilot study using proximity extension assay of cerebrospinal fluid and its extracellular vesicles identifies novel amyotrophic lateral sclerosis biomarker candidates. Sjoqvist S; Otake K Biochem Biophys Res Commun; 2022 Jul; 613():166-173. PubMed ID: 35567903 [TBL] [Abstract][Full Text] [Related]
19. Aberrant Levels of Cystatin C in Amyotrophic Lateral Sclerosis: a Systematic Review and Meta Analysis. Zhu Y; Yang M; Li F; Li M; Xu Z; Yang F; Liu Y; Chen W; Zhang Y; Xu R Int J Biol Sci; 2018; 14(9):1041-1053. PubMed ID: 29989057 [TBL] [Abstract][Full Text] [Related]
20. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. Wuolikainen A; Jonsson P; Ahnlund M; Antti H; Marklund SL; Moritz T; Forsgren L; Andersen PM; Trupp M Mol Biosyst; 2016 Apr; 12(4):1287-98. PubMed ID: 26883206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]